secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001824293-24-000049
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports Q1 net loss $1.9M; cash $4.1M; Phase 2a IPF study interim data due Q3 2024
--------------------------------------------------------------------------------

- Net loss $1.9M for Q1 2024; R&D expenses $0.9M, G&A $1.0M.
- Cash and equivalents $4.1M as of March 31, 2024; public offering raised $5.5M gross in Feb 2024.
- GRI-0621 Phase 2a biomarker study in IPF: interim data Q3 2024, topline results Q4 2024.
- GRI-0803 for SLE: IND-enabling studies to complete Q3 2024; IND filing expected H2 2024.
- Expanded IP estate with Korean patent issuance and Canadian notice of allowance for NKT cell modulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000049/0001824293-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000049/val-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001824293-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer